Goldenwell Biotech (GWLL) Free Cash Flow (2019 - 2025)
Goldenwell Biotech (GWLL) has disclosed Free Cash Flow for 7 consecutive years, with -$30885.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Free Cash Flow fell 84.22% year-over-year to -$30885.0, compared with a TTM value of -$29132.0 through Sep 2025, up 74.13%, and an annual FY2024 reading of -$123077.0, down 8.77% over the prior year.
- Free Cash Flow was -$30885.0 for Q3 2025 at Goldenwell Biotech, down from $59381.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $59381.0 in Q2 2025 and bottomed at -$917090.0 in Q4 2022.
- Average Free Cash Flow over 5 years is -$89448.3, with a median of -$29010.0 recorded in 2024.
- The sharpest move saw Free Cash Flow tumbled 105675.35% in 2021, then skyrocketed 224.36% in 2025.
- Year by year, Free Cash Flow stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 97.92% to -$19076.0 in 2023, then plummeted by 32.89% to -$25351.0 in 2024, then decreased by 21.83% to -$30885.0 in 2025.
- Business Quant data shows Free Cash Flow for GWLL at -$30885.0 in Q3 2025, $59381.0 in Q2 2025, and -$32277.0 in Q1 2025.